Pfizer's Abrysvo maintains strong efficacy through 2nd RSV season, study finds

29 Feb 2024
www.fiercepharma.com
Phase 3Drug ApprovalClinical ResultVaccine
Pfizer's Abrysvo maintains strong efficacy through 2nd RSV season, study finds
Preview
Source: FiercePharma
In a phase 3 trial, a single dose of Pfizer’s Abrysvo continued to provide protection through a second respiratory syncytial virus season.
Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo has shown its staying power in older adults who received a single dose before the previous virus season.
In season two, Abrysvo was 78% effective against RSV-associated lower respiratory tract disease with at least three symptoms in people 60 and older, according to trial results released Thursday. After the first season of the RENOIR phase 3 study, Abrysvo’s efficacy was 89%.
The bivalent shot maintained its efficacy for both strains of the virus—the more common RSV A and RSV B, with efficacy for both strains exceeding 80%.
Abrysvo was approved in May of last year for adults 60 and older. Three months later, Pfizer tacked on an FDA nod for Abrysvo for pregnant women to protect their newborns.
While Abrysvo generated $890 million in sales in its first year on the market, it trailed GSK’s RSV vaccine Arexvy, which achieved sales of 1.2 billion pounds sterling ($1.5 billion).
The silver lining for Pfizer was that it made up ground on GSK in the fourth quarter with $515 million in sales versus 529 million pounds ($671 million) for Arexvy. Another positive, according to Pfizer's fourth-quarter earnings presentation, was the sales of Abrysvo for expectant mothers. They are eligible for the shot in weeks 32 through 36 of their pregnancy.
Sanofi and AstraZeneca compete with Pfizer in protecting infants from RSV. Their partnered antibody Beyfortus, which can be given to children up to 24 months old, raked in 547 million euros ($592 million) last year.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.